# Emergent BioSolutions Inc.: Form 10-Q for the period ended Mar 31, 2018

- Company: [Emergent BioSolutions Inc.](/companies/ebs.md) (CIK 1367644)
- Form: 10-Q
- Filed: 2018-05-04
- Accepted by EDGAR: May 4, 2018, 16:04 ET
- Period: 2018-03-31
- Accession: 0001367644-18-000023
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1367644/000136764418000023/form10-q032018.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1367644/000136764418000023/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-01-01 to 2018-03-31 | $117.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2018-01-01 to 2018-03-31 | $29.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2018-01-01 to 2018-03-31 | $40.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2018-01-01 to 2018-03-31 | −$9.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-01-01 to 2018-03-31 | $234.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-01-01 to 2018-03-31 | −$4.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-01-01 to 2018-03-31 | −$4.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-01-01 to 2018-03-31 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-01-01 to 2018-03-31 | 49,580,089 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2018-01-01 to 2018-03-31 | −$991.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2018-01-01 to 2018-03-31 | $11.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2018-01-01 to 2018-03-31 | $145.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-03-31 | $163.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-03-31 | $476.6m | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-31 | $1.07bn | us-gaap:Assets |
| Current liabilities | at 2018-03-31 | $86.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-03-31 | $187.2m | us-gaap:Liabilities |
| Long-term debt | at 2018-03-31 | $13.5m | us-gaap:LongTermDebtNoncurrent |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1367644/000136764418000023/form10-q032018.htm

Filed May 4, 2018.
Source: SEC EDGAR, the filing index for accession 0001367644-18-000023. Last ingested by Listed: Nov 4, 2026, 16:51 ET. No prices; not investment advice.
